We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

Metsera is engaged in the development of injectable ... address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...